Search Within

Ryan D Stephenson

Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Radiology, Department of (6)
  4. Solid Tumor Oncology Division (6)
  5. GSK Faculty (5)
  6. Hematologic Malignancies, Division of (5)

More Groups

People
  1. Howard Scher (6)
  2. Michael Morris (6)
  3. Steven Larson (5)
  4. Susan Slovin (5)
  5. Christina Hong (4)
  6. Dana Rathkopf (4)

More People

Years
  1. 2013 (1)
  2. 2012 (1)
  3. 2009 (3)
  4. 2008 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer (1)
  3. European Urology (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier Science, Inc. (1)
  3. Wiley Blackwell (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
    Journal Article

    Autio, K. A.; Pandit-Taskar, N.; Carrasquillo, J. A.; Stephenson, R. D.; Slovin, S. F.; Rathkopf, D. E.; Hong, C.; Heller, G.; Scher, H. I.; Larson, S. M.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • Bone scan index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer
    Journal Article

    Dennis, E. R.; Jia, X.; Mezheritskiy, I. S.; Stephenson, R. D.; Schoder, H.; Fox, J. J.; Heller, G.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II study of docetaxel and (153)Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Rathkopf, D.; Solit, D.; Carrasquillo, J.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
    Journal Article

    Morris, M. J.; Huang, D.; Kelly, W. K.; Slovin, S. F.; Stephenson, R. D.; Eicher, C.; Delacruz, A.; Curley, T.; Schwartz, L. H.; Scher, H. I.
    European Urology (2009)

    Fulltext@MSK | Save
  • Phase I study of docetaxel (Tax) and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Solit, D.; Rathkopf, D. E.; Carrasquillo, J. A.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save